Five-year cancer survival rates hit 70% as doctors credit screening, treatment...
RALEIGH, N.C. (WTVD) -- The American Cancer Society reports that the five-year relative cancer survival rate for all cancers combined hit 70% for people...
Stanford Cancer Institute features advancements in immunotherapy cancer treatments
Lawrence Fong M.D. ’92, the scientific director of the Fred Hutch Cancer Center’s Immunotherapy Integrated Research Center (IIRC), discussed his lab’s latest innovations in...
ICT01 Receives FDA Breakthrough Therapy in First Line for Unfit Patients...
ICT01 has received FDA breakthrough therapy designation as frontline therapy for patients with AML who are unfit for induction chemotherapy.
Source link
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious...
NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune...
Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval.
Shares of Novartis (NVS)...
Pemvidutide for MASH Earns FDA Breakthrough Therapy Designation
This article originally appeared on HCPLive®.The FDA has granted breakthrough therapy designation (BTD) for pemvidutide for the treatment of metabolic dysfunction–associated steatohepatitis (MASH).1“The...
Coya advances immune-based therapy for early dementia
Coya’s FDA clearance for COYA 302 opens new chapter in treating frontotemporal dementia – calming immune system rather than chasing symptoms. Texas-based clinical-stage...
First leukaemia patient to get pioneering drug on NHS says it...
Fergus WalshMedical editorChris Williams, 29, from Belfast was diagnosed with the same aggressive type of leukaemia as Oscar in 2021.When the cancer returned, he...